Dwarfism, Pituitary

Endocrinology
1
Pipeline Programs
3
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

M&
Merck & Co.RAHWAY, NJ
1 program
1
Recombinant human growth hormonePhase 41 trial
Active Trials
NCT01187550CompletedEst. Apr 2009
Pfizer
PfizerNEW YORK, NY
1 program
SomatrogonN/A1 trial
Active Trials
NCT06587035Recruiting50Est. Sep 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Merck & Co.Recombinant human growth hormone
PfizerSomatrogon

Clinical Trials (2)

Total enrollment: 50 patients across 2 trials

NCT01187550Merck & Co.Recombinant human growth hormone

Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen®

Start: Mar 2007Est. completion: Apr 2009
Phase 4Completed

A Study to Learn About Somatrogon in Patients With Pediatric Growth Hormone Deficiency (p GHD) in India.

Start: Jan 2025Est. completion: Sep 202850 patients
N/ARecruiting

Related Jobs in Endocrinology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 50 patients
3 companies competing in this space